NCT04922736Active, not recruiting
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to assess the degree of improvement seen patient reported outcomes after 30 sessions of UVA-1 therapy in treating systemic scleroderma, morphea, and sclerodermatous Graft-Versus-Host Disease. While patients have verbally reported improvement of their sclerosing skin disease with UVA-1, patient reported outcomes have not been rigorously studied. In sclerosing skin diseases where clinical change is difficult to measure, patient reported outcomes may offer a better way to study the impact of treatments like UVA-1. This will be a non-blinded, non-randomized prospective trial using UVA-1 phototherapy in patients with established sclerosing skin disease. Patients will report the severity of their condition using multiple patient reported outcomes and will also be analyzed using multiple clinical investigator assessments at the beginning and end of 30 treatment sessions.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 8 Jun 2021
- Start date
- 7 Jun 2021
- Primary completion date
- Jun 2027
- Lead sponsor
- University of Utah
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT04922736
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 7 Jun 2021 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- UV light therapy in the 4 weeks prior to entering the study
- Commercial tanning in the 4 weeks prior to entering the study
Other illness
- History of intolerance to ultraviolet light
- Any other condition that will disqualify the patient from the study in the opinion of the investigator
Other
- Inability to complete study visits
- Current pregnancy or planned pregnancy during the study period
Who the study is looking for
- Must be able to understand and provide written informed consent
- Must have a diagnosis of systemic scleroderma with cutaneous sclerosis, morphea, or sclerodermatous Graft vs. host disease based on the presence of characteristic clinical findings
- Age of at least 18-years-old
- Ability to engage in 30 UVA-1 treatments in a maximum of 100 days.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah Dermatology Coordinator of this site? Confirm its status | Murray | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.